New Method Uses Off-The-Shelf Antibodies to Steer CRISPR-Cas Particles for Targeted Cell Editing

A Stanford-led research team has developed a novel system, called designer antibody-routed nanoparticles (DARTs), that allows CRISPR-Cas particles to be precisely delivered to target cells using ordinary commercial antibodies. This method simplifies the targeting process, which previously required complex engineering, and has been shown to effectively edit neural progenitor cells in the fetal mouse brain.